SEARCH

SEARCH BY CITATION

References

  • Anderson S. M. and Brunzell D. H. (2012) Low dose nicotine and antagonism of beta2 subunit containing nicotinic acetylcholine receptors have similar effects on affective behavior in mice. PLoS ONE 7, e48665.
  • Artymyshyn R., Smith A. and Wolfe B. B. (1990) The use of 3H standards in 125I autoradiography. J. Neurosci. Methods 32, 185192.
  • Berthet A. and Bezard E. (2009) Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat. Disord. 15(Suppl 4), S8S12.
  • Bezard E., Brotchie J. M. and Gross C. E. (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577588.
  • Bordia T., Grady S. R., McIntosh J. M. and Quik M. (2007) Nigrostriatal damage preferentially decreases a subpopulation of {alpha}6{beta}2* nAChRs in mouse, monkey and Parkinson's disease striatum. Mol. Pharmacol. 72, 5261.
  • Bordia T., Campos C., Huang L. and Quik M. (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 327, 239247.
  • Bordia T., Campos C., McIntosh J. M. and Quik M. (2010) Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J. Pharmacol. Exp. Ther. 333, 929938.
  • Bordia T., Hrachova M., Chin M., McIntosh J. M. and Quik M. (2012) Varenicline is a potent partial agonist at alpha6beta2* nAChRs in rat and monkey striatum. J. Pharmacol. Exp. Ther. 342, 327334.
  • Brotchie J. and Jenner P. (2011) New approaches to therapy. Int. Rev. Neurobiol. 98, 123150.
  • Buccafusco J. J., Beach J. W. and Terry A. V. (2009) Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther. 328, 364370.
  • Carta M. and Bezard E. (2011) Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience 198, 245251.
  • Carta M., Lindgren H. S., Lundblad M., Stancampiano R., Fadda F. and Cenci M. A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96, 17181727.
  • Carta M., Carlsson T., Kirik D. and Bjorklund A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 18191833.
  • Cenci M. A. (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 30, 236243.
  • Cenci M. A. and Konradi C. (2010) Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog. Brain Res. 183C, 209233.
  • Cenci M. and Lindgren H. (2007) Advances in understanding l-DOPA-induced dyskinesia. Curr. Opin. Neurobiol. 17, 665671.
  • Cenci M. A. and Lundblad M. (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 9.25.1–9.25.3.
  • Dopico A. M. and Lovinger D. M. (2009) Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol. Rev. 61, 98114.
  • Exley R., Maubourguet N., David V. et al. (2011) Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine. Proc. Natl Acad. Sci. USA 108, 75777582.
  • Fisone G. and Bezard E. (2011) Molecular mechanisms of l-DOPA-induced dyskinesia. Int. Rev. Neurobiol. 98, 95122.
  • Fisone G., Hakansson K., Borgkvist A. and Santini E. (2007) Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol. Behav. 92, 814.
  • Gotti C., Guiducci S., Tedesco V. et al. (2010) Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J. Neurosci. 30, 53115325.
  • Grady S., Marks M. J., Wonnacott S. and Collins A. C. (1992) Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59, 848856.
  • Grady S. R., Murphy K. L., Cao J., Marks M. J., McIntosh J. M. and Collins A. C. (2002) Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J. Pharmacol. Exp. Ther. 301, 651660.
  • Grady S. R., Drenan R. M., Breining S. R. et al. (2010a) Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology 58, 10541066.
  • Grady S. R., Salminen O., McIntosh J. M., Marks M. J. and Collins A. C. (2010b) Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors. J. Mol. Neurosci. 40, 9195.
  • Huang L., Grady S. R. and Quik M. (2011a) Nicotine reduces L-dopa-induced Dyskinesias by acting at {beta}2 nicotinic receptors. J. Pharmacol. Exp. Ther. 338, 932941.
  • Huang L. Z., Campos C., Ly J., Carroll F. I. and Quik M. (2011b) Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats. Neuropharmacology 60, 861868.
  • Hukkanen J., Jacob P. III and Benowitz N. L. (2005) Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79115.
  • Jenner P. (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9, 665677.
  • Lai A., Parameswaran N., Khwaja M., Whiteaker P., Lindstrom J. M., Fan H., McIntosh J. M., Grady S. R. and Quik M. (2005) Long-term nicotine treatment decreases striatal alpha6* nicotinic acetylcholine receptor sites and function in mice. Mol. Pharmacol. 67, 16391647.
  • Lindgren H. S., Andersson D. R., Lagerkvist S., Nissbrandt H. and Cenci M. A. (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 112, 14651476.
  • Lundblad M., af Bjerken S., Cenci M. A., Pomerleau F., Gerhardt G. A. and Stromberg I. (2009) Chronic intermittent L-DOPA treatment induces changes in dopamine release. J. Neurochem. 108, 9981008.
  • Marks M. J., Pauly J. R., Gross S. D., Deneris E. S., Hermans-Borgmeyer I., Heinemann S. F. and Collins A. C. (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12, 27652784.
  • Marks M. J., Wageman C. R., Grady S. R., Gopalakrishnan M. and Briggs C. A. (2009) Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. Biochem. Pharmacol. 78, 795802.
  • McCallum S., Parameswaran N., Bordia T., Fan H., McIntosh M. and Quik M. (2006) Differential regulation of mesolimbic {alpha}3*/{alpha}6{beta}2* and {alpha}4{beta}2* nAChR sites and function after long-term oral nicotine to monkeys. J. Pharmacol. Exp. Ther. 318, 381388.
  • McIntosh J. M., Azam L., Staheli S., Dowell C., Lindstrom J. M., Kuryatov A., Garrett J. E., Marks M. J. and Whiteaker P. (2004) Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. Mol. Pharmacol. 65, 944952.
  • Meissner W., Ravenscroft P., Reese R. et al. (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 22, 586598.
  • Moretti M., Mugnaini M., Tessari M., Zoli M., Gaimarri A., Manfredi I., Pistillo F., Clementi F. and Gotti C. (2010) A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Mol. Pharmacol. 78, 287296.
  • Mugnaini M., Garzotti M., Sartori I., Pilla M., Repeto P., Heidbreder C. A. and Tessari M. (2006) Selective down-regulation of [(125)I]Y(0)-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine. Neuroscience 137, 565572.
  • Munoz A., Li Q., Gardoni F. et al. (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131, 33803394.
  • Murer M. G. and Moratalla R. (2011) Striatal signaling in L-DOPA-induced Dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front. Neuroanat. 5, 51.
  • Nahimi A., Holtzermann M., Landau A. M. et al. (2012) Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. J. Neurochem. 120, 806817.
  • Pavese N., Evans A. H., Tai Y. F., Hotton G., Brooks D. J., Lees A. J. and Piccini P. (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67, 16121617.
  • Perez X. A., Bordia T., McIntosh J. M., Grady S. R. and Quik M. (2008) Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function. Mol. Pharmacol. 74, 844853.
  • Perez X., O'Leary K., Parameswaran N., McIntosh J. M. and Quik M. (2009) Prominent role of {alpha}3/{alpha}6{beta}2* nAChRs in regulating evoked dopamine release in primate putamen; effect of long-term nicotine treatment. Mol. Pharmacol. 75, 938946.
  • Perry D. C., Mao D., Gold A. B., McIntosh J. M., Pezzullo J. C. and Kellar K. J. (2007) Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain. J. Pharmacol. Exp. Ther. 322, 306315.
  • Picciotto M. R., Addy N. A., Mineur Y. S. and Brunzell D. H. (2008) It is not “either/or”: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog. Neurobiol. 84, 329342.
  • Quik M. and Wonnacott S. (2011) {alpha}6{beta}2* and {alpha}4{beta}2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 63, 938966.
  • Quik M., Sum J. D., Whiteaker P., McCallum S. E., Marks M. J., Musachio J., McIntosh J. M., Collins A. C. and Grady S. R. (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol. Pharmacol. 63, 11691179.
  • Quik M., Cox H., Parameswaran N., O'Leary K., Langston J. W. and Di Monte D. (2007) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann. Neurol. 62, 588596.
  • Quik M., Mallela A., Chin M., McIntosh J. M., Perez X. A. and Bordia T. (2013) Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiol. Dis. 50, 3041.
  • Quik M., Park K. M., Hrachova M., Mallela A., Huang L. Z., McIntosh J. M. and Grady S. R. (2012b) Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology 63, 450459.
  • Rapier C., Lunt G. G. and Wonnacott S. (1990) Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation. J. Neurochem. 54, 937945.
  • Rascol O., Fitzer-Attas C. J., Hauser R. et al. (2011) A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 10, 415423.
  • Salminen O., Murphy K. L., McIntosh J. M., Drago J., Marks M. J., Collins A. C. and Grady S. R. (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65, 15261535.
  • Schallert T., Fleming S. M., Leasure J. L., Tillerson J. L. and Bland S. T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777787.
  • Schapira A. H. and Jenner P. (2011) Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 26, 10491055.
  • Wonnacott S., Kaiser S., Mogg A., Soliakov L. and Jones I. W. (2000) Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol. 393, 5158.
  • Zhao-Shea R., Liu L., Soll L. G. et al. (2011) Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology 36, 10211032.
  • Zoli M., Moretti M., Zanardi A., McIntosh J. M., Clementi F. and Gotti C. (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22, 87858789.